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Abstract
Glycoengineering aimed at addition of carbohydrates to proteins is an attractive approach to alter 
pharmacokinetic properties of proteins such as enhancing stability and prolonging the duration of 
action. We report a novel protein glyco-modification of BSA and recombinant thrombomodulin 
with O-cyanate chain-end functionalized glycopolymer via isourea bond formation. The protein 
glycoconjugates were confirmed by SDS-PAGE, western blot, and MALDI-TOF Mass 
Spectrometry. Protein C activation activity of the glyco-modified recombinant thrombomodulin 
was confirmed, proving no interference to activity from the glycopolymer modification. The 
isourea bond formation under mild conditions was demonstrated as an alternative method for 
protein modification with polymers.
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1. introduction
Protein-based drugs have revolutionized the treatment of many diseases and could be the 
major clinically used drugs in the future. However, many limitations, such as rapid clearance 
and instability, still prevent their practical utility. In particular, these limitations often lead to 
high frequency of protein administration required to maintain therapeutic dosages, which 
places a substantial burden on both patients and caregivers from both convenience and cost 
standpoints. Many efforts have been made towards enhancing protein half-life so as to 
reduce administration frequency and thus increase convenience and improve patient 
compliance. Modification of protein with water-soluble polymers, such as polyethylene 
glycol (PEG), has proven effective in increasing the circulation time of the drug in vivo by 
attenuating renal filtration, thus decreasing clearance and has been approved in clinical 
usage.[1] Glycoengineering aimed at addition of carbohydrates to proteins is an attractive 
approach to alter pharmacokinetic properties of proteins such as increasing stability and 
prolonging the duration of action.[2] A successful example is the discovery of darbepoetin 
alfa, an erythropoietin analogue that contains additional carbohydrates resulting in a
threefold increase in serum half-life and increased in vivo activity compared to recombinant 
human erythropoietin.[3] Synthetic polymers have been widely investigated for protein 
modification for profound biological applications.!4] Glycopolymers that contain multiple 
copies of sugar moieties have been employed as natural oligosaccharide mimics and found 
important biological applications in biosensor, microarray and protein modification.!5] For 
example, a maleimide functionalized glycopolymer was developed for synthesizing 
glycoprotein mimics by modifying thiol-containing residues of proteins.[6] Therefore, 
glycoengineering of therapeutic proteins with covalently attached glycopolymers is expected 
to provide an effective route to improve proteins’ stability and extend their plasma half-life 
and also to reduce their immunogenicity as well.
Amine-targeted bioconjugations have been the major strategy for protein modification. 
Amide bond formation and reductive amination are the most used methods; however, low 
reaction efficiency and pH-dependent reaction conditions often limit their wide 
applications. [7] Alternatively, O-cyanate-based isourea bond formation has been proven 
useful as an amine-targeted bioconjugation technique for protein immobilization.[8,9] 
Cyanoxyl-mediated free radical polymerization (CMFRP) has been developed as a 
straightforward approach for synthesizing glycopolymers.[10] Recently, we demonstrated 
that CMFRP is a facile method for the synthesis of O-cyanate chain-end functionalized 
glycopolymers, which can be immobilized onto amine surface for oriented glyco- 
macroligand formation via isourea bond.[11,12] We found that CMFRP possesses several 
advantages such as direct polymerization, reaction in aqueous solution, exclusion of tedious 
protection and deprotection steps, compatibility with a broad range of functional groups, and 
a O-cyanate chain-end group. The presence of chain-terminal O-cyanate group allows for 
conjugation to amine group through isourea bond formation, a reaction that has been well 
understood, characterized, and used for affinity chromatography. Therefore, we envisioned 
that the chain-end O-cyanate group of the glycopolymer provides an anchor for site-specific 
and covalent conjugation of the glycopolymer with protein amine groups via isourea bond 
formation and thereby facilitates a site-specific glycopolymer-protein conjugate formation 
(Figure 1).
Thrombomodulin (TM) is an endothelial membrane protein and acts as a physiological 
anticoagulant by binding thrombin and subsequently converting protein C to its active form 
(APC), which is an anticoagulant protease that selectively inactivates coagulation factors Va 
and VIIIa.[13] TM epidermal growth factor-like domains 4-6 (TM456) are the minimum 
required domains for TM anticoagulant activity.[14] Therefore, TM456 serves as a potential 
candidate for an antithrombotic agent. However, the half-life of the TM456 is extremely 
short compared to recombinant human soluble thrombomodulin (rhsTM), and thus limits its 
clinical application.[15] Herein, we proposed that the modification of TM456 with a 
glycopolymer could enhance its pharmacokinetic properties. In this study, we investigated 
protein glyco-modification with O-cyanate chain-end functionalized glycopolymer with 
bovine serum albumin (BSA) as a model protein and then with recombinant
thrombomodulin (rTM456) as an anticoagulant agent. Both polymer-protein conjugates were 
generated via isourea bond formation between the amino and O-cyanate functional group.
2. Results and discussion
CMFRP is a versatile technique to synthesize polymers with multivalent carbohydrates 
pendants on the polymer backbone and an O-cyanate at the polymer chain end. In this study, 
lactose-based O-cyanate chain-end functionalized glycopolymer was synthesized from 
acrylaminoethyl lactoside via CMFRP as in our previous report.[16] As shown in Scheme 1, 
acrylamide was used in the polymerization with acrylaminoethyl lactoside so as to control 
the carbohydrate density as well as the solubility of the polyacrylamide polymer. 
Polyacrylamide also provides stability to chemical and proteolytic cleavage. Another feature 
is that the presence of a terminal phenyl group in the polymer allows for easy determination 
of lactose and acrylamide content as well as average molecular weight of the glycopolymer 
by 1H NMR spectrum.[17] In addition, in our previous work we were able to show that low 
polydispersity (Mw/Mn<1.6) glycopolymers could be produced using this approach.[18]
First, BSA was used as a model protein to test the feasibility of O-cyanate chain-end 
functionalized glycopolymer modification via isourea bond formation. BSA contains 57 
lysine residues, which allow for multiple polymer modifications with O-cyanate functional 
groups. The conjugation reaction between BSA and glycopolymer was run in bicarbonate 
buffer (pH 8.3) for 24 hours at 4 °C. The successful conjugation of BSA and glycopolymer 
was confirmed by SDS-PAGE with an observed increased in molecular weight of BSA 
conjugates. As shown in Figure 2, the presence of protein was verified by typical Coomassie 
blue staining (Figure 2A), while the presence of carbohydrates was confirmed by 
carbohydrate-specific staining (Shiff's base formation, Figure 2B) and whole protein 
staining (Figure 2C). The carbohydrate-specific staining method is based on periodic acid- 
Schiff base formation, where carbohydrate cis-diol groups are oxidized to aldehydes by 
periodic acid. Subsequent reaction with fuchsine reagent forms a Schiff base between the 
aldehydes and the amino groups of the dye allowing for carbohydrate visualization. As a 
result, BSA-glycopolymer conjugate was visualized (Figure 3B, Lane 4), while BSA was 
not stained by the carbohydrate staining (Figure 2B, Lanes 3). The glycopolymer was not 
observed on the gel with carbohydrate staining (Figure 3B, Lane 2), possibly due to its 
neutral and hydrophilic property. The hydrophilic nature of the molecule prevented it from 
interacting with SDS thus leading to a lower negative charge density, resulting in reduced 
motility during electrophoresis. On the SDS-PAGE, the observed molecular weight of the 
glycopolymer-protein conjugate was higher than anticipated. This could be due to the fact 
that the attached glycopolymer contains long hydrophilic backbone with side chains 
consisting of lactose and amide functionalities, which prevent SDS from interacting with the 
protein and thus hamper the conjugate to move through the gel during electrophoresis. This 
phenomenon has been observed in a previous report when using glycopolymer to modify 
streptavidin via biotin binding.[17] These results indicated that the O-cyanate chain-end 
functionalized glycopolymer could be used for protein modification via isourea bond 
formation with site-specificity. In addition, the BSA-glycopolymer conjugate was also 
confirmed by using Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI- 
TOF) mass spectrometry (Figure 3). The BSA-glycopolymer conjugate displayed an 
approximately 71 kDa molecular weight, which is about 5 kDa higher than BSA (66.6 kDa).
All these results indicated a successful BSA-glycopolymer conjugation via isourea bond 
formation.
Next, the O-cyanate chain-end functionalized glycopolymer was used for glyco- 
modification of recombinant TM (rTM456). The conjugation reaction between rTM456 and 
glycopolymer was run in a Tris-HCl buffer since it was found that rTM456 precipitated 
easily when the buffer conditions were changed. Thus, the same buffer used for rTM456 
purification was applied for the conjugation reaction. The conjugate formation was 
confirmed by SDS-PAGE, in which the glycoconjugate was visualized by carbohydrate 
staining (Figure 4A, Lane 3), total protein staining (Figure 4B, Lane 3) and western blot 
using mouse monoclonal antibody specific to human TM (Figure 4C, Lane 3), while rTM456 
(without modification) was observed at around 16 kDa by total protein staining (Figure 4B, 
Lane 1) and western blot using mouse monoclonal antibody specific to human TM (Figure 
4C, Lane 1). No conjugate was formed in the reaction mixture of rTM456 and a 
glycopolymer with a hydroxyl group (Figure 4A, 4B and 4C, Lane 2), which was obtained 
by treating the O-cyanate chain-end functionalized glycopolymer with pyridine in water, a 
procedure that we had reported previously.[15] The lack of reaction with the hydroxyl- 
terminated glycopolymer confirmed that a glycoconjugate was formed via isourea bond. The 
apparent high molecular weight of the glycoconjugates may be due to a similar phenomenon 
as discussed above, namely that glycopolymer attachment to rTM456 prevented SDS 
homogenous coverage of the molecule thus preventing the formation of homogenous 
negative charge throughout the protein's surface, which affected the rate at which the 
glycoconjugates moved through the acrylamide gel. Finally, MALDI TOF analysis of the 
rTM456-glycopolymer conjugate revealed an increase of molecular weight of the conjugate 
to 21 kDa (Figure 4B), approximately 5 kDa higher than the unreacted TM (Figure 4A). All 
these results indicated the successful rTM456-glycopolymer conjugation via isourea bond 
formation.
Based on the MALDI-TOF MS results, a 5 kDa molecular weight increase was observed for 
both BSA-glycopolymer and rTM-glycopolymer, suggesting the formation of 1:1 
conjugates. BSA contains 57 lysine residues and a terminal amine and rTM456 contains one 
lysine residue and a terminal amine. Since the pKa of a terminal amine is close to 7-8 and 
that of lysine amino groups is near 9, we suspect that the reaction at pH 8.0-8.3 resulted in 
the specific modification of the terminal amine of both proteins. In addition, steric hindrance 
might have blocked polymer modification on the other sites of proteins. A more detailed 
investigation of the specificity of modification is needed in our continued study.
TM is an endothelial membrane protein and acts as an anticoagulant by binding to thrombin 
and subsequently converting protein C to its active form (APC), which selectively 
inactivates coagulation factors Va and VIIIa.[13] In this study, the protein C activation 
activities of rTM456 (control) and rTM456-glycopolymer were assessed using a previously 
established method.[19] As a result, rTM456-glycopolymer showed the similar protein C 
activation activity to rTM456 for both Michaelis constant (Km) and turnover number (kcat) 
(Table 1), meaning that the glycopolymer modification did not negatively affect the rTM456 
activity.
3. Conclusions
In this study, we have demonstrated a novel strategy for protein modification with ()- 
cyanate chain-end functionalized glycopolymer via isourea bond formation. This 
modification provides beneficial properties for possible therapeutic applications of proteins. 
In particular, single chain-end O-cyanate group provides an anchor point by its specific 
conjugation with amine groups of proteins and facilitates highly oriented assembly of the 
glycopolymer. In addition, the ease of synthesis of O-cyanate chain-end functionalized 
glycopolymers via CMFRP and the mild conditions for isourea bond formation in different 
buffers make this approach versatile and general for primary amine-oriented protein 
modification.
4. Experimental
4.1. Materials and methods
All solvents and reagents were purchased from commercial sources and were used as 
received, unless otherwise noted. Deionized water was used for reactions, dialyses, and 
measurements. Dialyses were performed using cellulose membranes. 12.5% Polyacrylamide 
gels were cast using Mini-PROTEAN® Tetra Handcast System from Biorad (Hercules,
CA). Electrophoresis was performed at 130 V for 120 min. at room temperature. 
Glycoprotein and RAPID stain total protein stains were obtained as a kit from G- 
Biosciences (St. Louis, MO). Bovine serum albumin (BSA) and sinapic acid (SA for 
MALDI matrix) were obtained from Sigma-Aldrich (St. Louis, MO). Purified recombinant 
human PC and human thrombin were from Haematologic Technologies Inc. (Essex 
Junction, VT). Human antithrombin III and chromogenic substrate Spectrozyme PCa were 
purchased from American Diagnostica Inc. (Stamford, CT). 1H NMR spectra were obtained 
from Bruker HD 400 NMR spectrometer at room temperature. All sample concentrations 
were 10 mg mL-1, and appropriate deuterated solvents were used. UV-vis absorbance 
measurements were performed on a Varian Bio50 UV-vis spectrometer. MALDI TOF 
spectra were obtained using Bruker Autoflex III smartbeam spectrometer.
4.2. Synthesis of O-cyanate chain-end functionalized glycopolymer
4.2.1. Synthesis of lactosyl acrylamide (2-N-acryloyl-aminoethoxyl-4-O-(β-D- 
galactopyranosyl)-β-D-glycopyranoside)—The lactosyl acrylamide was synthesized 
by following our previous report.[16]
4.2.2. Polymerization—Sodium nitrite (7 mg, 1.0 mmol) and 4-chloroaniline (11 mg, 
0.09 mmol) were dissolved in 3 mL mixture of H2O/THF (1:1, V/V), followed by adding 
HBF4 (122 mg, 1.5 mmol) then incubating for 30 mins. Next, lactosyl acrylamide monomer 
(90 mg, 13 μmol), NaOCN (27 mg, 0.42 mmol) and acrylamide (105 mg, 13 μmol) were 
added. The reaction solution was incubated for 16 h at 60 °C, followed by dialysis (3500 Da 
Mw cutoff) to afford lactose-based O-cyanate chain-end functionalized glycopolymer (275 
mg, 65% yield). The O-cyanate chain-end functionalized glycopolymer was characterized 
by 1H and 13C NMR spectroscopy (Supporting Information Figures S1 and S2).
4.2.3. Conversion of O-cyanate group to hydroxyl group of the glycopolymer
—The chain-end O-cyanate group of glycopolymer was converted to a hydroxyl group by 
the reaction with pyridine in water as in our previous report.!18]
4.3. Synthesis of BSA-glycopolymer conjugate
BSA (0.2 mg) was reacted with O-cyanate chain-end functionalized glycopolymer (4 mg) in 
16 μL of 0.1 M NaHCO3 (pH 8.3) containing 0.5 M NaCl at 4 °C for 24 hours. The reaction 
mixture was dialyzed (13 kDa cutoff) against DI water to remove the unreacted 
glycopolymer and buffer solution and then was lyophilized to afford the BSA-glycopolymer 
conjugate (0.4 mg).
4.4. Characterization of BSA-glycopolymer conjugate
BSA-glycopolymer conjugate was analyzed by SDS PAGE, followed by Coomassie blue 
and carbohydrate staining, respectively. Coomassie blue staining was performed by 
following the Laemmli method[20] under reducing and non-reducing condition.
Carbohydrate staining was conducted by following the protocol provided with the glyco- 
staining kit (G-Biosciences, St. Louis, MO). MALDI TOF experiments were carried out by 
first dissolving the material in water (1 mg/mL), then mixing with a saturated sinapic acid 
matrix solution (Water:Acetonitrile:Trifluoroacetic Acid, 50:50:0.1, v/v ratio). Then, 1 μL of 
the sample was deposited on MALDI MS steel plate, dried and analyzed by Bruker Autoflex 
III smartbeam spectrometer in linear positive mode.
4.5. Expression and purification of recombinant thrombomodulin EGF4,5,6 domains 
(rTM456
The rTM456 was prepared by transformation of expression plasmid encoding rTM456 into E. 
coli BL21 (DE3) as previously reported.[19] Briefly, bacteria were grown in LB medium 
with 35 mg/L kanamycin at 37 °C. Upon obtaining a value of OD600nm between 0.8 and 1.0, 
protein expression was induced with the addition of IPTG (isopropyl-β-D-1- 
thiogalactopyranoside, 0.5 mM), and the culture was incubated overnight at 25°C. Cells 
were harvested by centrifugation for 30 min. at 8000 x g at 4 °C. The pellets were collected 
and dissolved in a cell lysis buffer (20 mM Tris-HCl, 300 mM NaCl, pH 8.0) to induce cell 
membrane rupturing and release of cytosolic proteins. In order to prevent cytosolic protein 
breakdown by cellular proteases, a serine protease inhibitor, PMSF (10 pg/mL), was added. 
The cells were then sonicated with a probe sonicator (Sonifier 450, Branson Ultrasonics,
CT, USA) 10 times for 30 sec., followed by 2 min. storage on ice after every sonication.
Cell disruption was evident after partial clearing of the suspension. The broken cells were 
then centrifuged at 15000 x g for 30 min. and the supernatant was collected for purification. 
The supernatant was directly applied to an immobilized metal affinity chromatography 
column (HisTrap FF, GE), which was previously equilibrated with a washing buffer (20 mM 
Tris-HCl, 300 mM NaCl, 20 mM imidazole, pH 8.0). The column was washed with 10 
column volumes of washing buffer then flushed with 3 column volumes of elution buffer 
(20 mM Tris-HCl, 300 mM NaCl, 250 mM imidazole, pH 8.0) to afford ‘His’ and ‘S’ tagged 
rTM456. Finally, recombinant enterokinase was used for site-specific cleavage to remove the 
fusion tags and generate the target protein rTM456. Recombinant enterokinase was removed
by following instruction from kit, and digested solution was loaded into Ni2+ affinity 
chromatography to remove cleaved tag. The target protein, rTM456 was collected after 
passing through chromatography and dialyzed against Tris-HCl buffer (pH 8.0) and 
characterized by SDS-PAGE (17 kDa MW).
4.6. Synthesis and characterization of rTM456-glycopolymer conjugate
20 pL of 20 mM Tris-HCl buffer solution (pH 8.0)containing 2 mg of O-cyanate chain-end 
functionalized glycopolymer was added to 100 pL of the same buffer containing a solution 
containing 10 μg (0.6 nmol) of rTM456. The mixture was stirred at 4 °C for 24 h. Then the 
reaction mixture was dialyzed (13 kDa cutoff) against DI water for 48 h to remove the 
unreacted glycopolymer and then lyophilized to afford the rTM456-glycopolymer conjugate 
(20 μg). The control reaction of rTM456 with OH-terminated glycopolymer was conducted 
under the same conditions as above. SDS-PAGE gel (12.5%) was run, followed by glyco- 
staining and total protein staining to confirm the reaction product by following the 
manufacturer procedure (GBiosciences). Western blot of rTM456, rTM456 reacted with O- 
cyanate-terminated glycopolymer and rTM456 reacted with OH-terminated glycopolymer 
were performed using mouse monoclonal antibody specific to human thrombomodulin, 
respectively. MALDI TOF experiments were carried out by first dissolving the rTM456- 
glycopolymer conjugate in water (1 mg/mL) and then mixing with a saturated sinapic acid 
matrix solution (Water:Acetonitrile:Trifluoroacetic Acid, 50:50:0.1, v/v ratio). 1 μL of 
sample was then deposited on polished steel plate, dried and sampled.
4.7. Protein C activation activity of rTM456-glycopolymer conjugate
Activation experiments were conducted at 37 °C in 20 mM Tris-HCl buffer, pH 7.4, 
containing 100 mM NaCl, 0.1% BSA, and 5 mM Ca2+. Protein activation solution contained 
0.5 nM of rTM456, 5 nM of thrombin, and 0.1 pM of protein C. Activation was stopped by 
adding antithrombin III (300 μg/mL final concentration). The activated protein C present 
was measured by hydrolysis of Spectrozyme PCa at 25 °C in 0.1 M NaCl, 0.02 M Tris-HCl, 
pH 7.4, containing 1 mg mL-1 of BSA. The produced active PC was measured through 
hydrolysis of Spectrozyme PCa by comparing a standard curve, in which the concentration 
of active PC to the rate of pnitroanilide (pNA) formation was measured. The hydrolysis of 
Spectrozyme PCa was performed for 10 min in the assay buffer at 37 °C, in which pNA was 
produced and its concentration measured by monitoring at λ = 405 nm with a UV 
spectrophotometer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was partly supported by grants from the NIH (1R01HL102604-04, X.-L. Sun), National Science 
Foundation MRI Grant (CHE-1126384, X.-L. Sun), Faculty Research Development Fund and the research fund at 
the Center for Gene Regulation in Health and Disease (GRHD) at Cleveland State University supported by Ohio 
Department of Development (ODOD). MALDI TOF data was supported by the National Science Foundation under 
Grant No. MRI-0821515 at Case Western Reserve University.
References
1. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs : clinical 
immunotherapeutics, biophannaceuticals and gene therapy. 2008; 22:315-29.
2. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic 
proteins. Journal of pharmaceutical sciences. 2005; 94:1626-35. [PubMed: 15959882]
3. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, 
Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund 
T, Rogers G, Rogers N, Trail G, Egrie J. Enhancement of therapeutic protein in vivo activities 
through glycoengineering. Nature biotechnology. 2003; 21:414-21.
4. Grover GN, Maynard HD. Protein-polymer conjugates: synthetic approaches by controlled radical 
polymerizations and interesting applications. Current opinion in chemical biology. 2010; 14:818- 
27. [PubMed: 21071260]
5. Wang Q, Dordick JS, Linhardt RJ. Synthesis and application of carbohydrate-containing polymers. 
Chemistry of Materials. 2002; 14:3232-3244.
6. Geng J, Mantovani G, Tao L, Nicolas J, Chen G, Wallis R, Mitchell DA, Johnson BR, Evans SD, 
Haddleton DM. Site-directed conjugation of “clicked” glycopolymers to form glycoprotein mimics: 
binding to mammalian lectin and induction of immunological function. Journal of the American 
Chemical Society. 2007; 129:15156-63. [PubMed: 18020332]
7. Basle E, Joubert N, Pucheault M. Protein chemical modification on endogenous amino acids. Chem. 
Biol. 2010; 17:213-227. [PubMed: 20338513]
8. Porath J, Axen R, Emback S. Chemical coupling of proteins to agarose. Nature. 1967; 215:1491- 
1492. [PubMed: 6059570]
9. Tugulu S, Silacci P, Stergiopulos N, Klok HA. RGD-Functionalized polymer brushes as substrates 
for the integrin specific adhesion of human umbilical vein endothelial cells. Biomaterials. 2007; 
28:2536-46. [PubMed: 17321591]
10. Grande D, Baskaran S, Baskaran C, Gnanou Y, Chaikof EL. Glycosaminoglycan-mimetic 
biomaterials. 1. Nonsulfated and sulfated glycopolymers by cyanoxyl-mediated free-radical 
polymerization. Macromolecules. 2000; 33:1123-1125.
11. Narla SN, Sun XL. Orientated glyco-macroligand formation based on site-specific immobilization 
of O-cyanate chain-end functionalized glycopolymer. Organic & biomolecular chemistry. 2011; 
9:845-50. [PubMed: 21116566]
12. Narla SN, Sun XL. Glyco-macroligand microarray with controlled orientation and glycan density. 
Lab on a chip. 2012; 12:1656-63. [PubMed: 22422059]
13. Esmon CT, Gu JM, Xu J, Qu D, Stearns-Kurosawa DJ, Kurosawa S. Regulation and functions of 
the protein C anticoagulant pathway. Haematologica. 1999; 84:363-8. [PubMed: 10190952]
14. Zushi M, Gomi K, Yamamoto S, Maruyama I, Hayashi T, Suzuki K. The last three consecutive 
epidermal growth factor-like structures of human thrombomodulin comprise the minimum 
functional domain for protein C-activating cofactor activity and anticoagulant activity. The Journal 
of biological chemistry. 1989; 264:10351-3. [PubMed: 2543666]
15. Suzuki M, Mohri M, Yamamoto S. In vitro anticoagulant properties of a minimum functional 
fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in 
extracorporeal circulation using a monkey model. Thrombosis and haemostasis. 1998; 79:417-22. 
[PubMed: 9493601]
16. Sun XL, Grande D, Baskaran S, Hanson SR, Chaikof EL. Glycosaminoglycan mimetic 
biomaterials. 4. Synthesis of sulfated lactose-based glycopolymers that exhibit anticoagulant 
activity. Biomacromolecules. 2002; 3:1065-1070. [PubMed: 12217054]
17. Sun XL, Faucher KM, Houston M, Grande D, Chaikof EL. Design and synthesis of biotin chain- 
terminated glycopolymers for surface glycoengineering. Journal of the American Chemical 
Society. 2002; 124:7258-9. [PubMed: 12071720]
18. Hou S, Sun XL, Dong CM, Chaikof EL. Facile synthesis of chain-end functionalized 
glycopolymers for site-specific bioconjugation. Bioconjugate chemistry. 2004; 15:954-9.
[PubMed: 15366947]
19. Zhang H, Weingart J, Jiang R, Peng J, Wu Q, Sun XL. Bio-inspired liposomal thrombomodulin 
conjugate through bio-orthogonal chemistry. Bioconjugate chemistry. 2013; 24:550-9. [PubMed: 
23458546]
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. 
Nature. 1970; 227:680-685. [PubMed: 5432063]
Glycopolymer
Figure 1.
Protein glyco-modification with O-cyanate chain-end functionalized glycopolymer via 
isourea bond formation.
Figure 2.
12.5 % SDS-PAGE of BSA-glycopolymer conjugate: (A). Coomassie blue staining, (B). 
Carbohydrate staining, (C). Total protein staining. (Lane 1: glycoprotein molecular marker, 
Lane 2: glycopolymer, Lane 3: BSA, Lane 4: BSA-glycopolymer conjugate). Molecular 
weights are indicated in kDa.
Figure 3.
MALDI TOF spectrum of BSA (red) showing a single peak at 66.6 kDa and BSA- 
glycopolymer (pink) showing two peaks at approximately 66.6 kDa (unreacted BSA) and 
71.7 kDa (reacted) (Matrix:Water:Acetonitrile:Trifluoroacetic Acid, 50:50:0.1, v/v ratio).
Figure 4.
12.5 % SDS-PAGE of rTM4,5,6-glycopolymer conjugate: (A). carbohydrate staining, (B). 
total protein staining and (C). Western blot with mouse anti-TM antibody (Lane 1: rTM456, 
Lane 2: rTM456 reacted with OH-terminated glycopolymer, Lane 3: rTM456 reacted with 
OCN-terminated glycopolymer).
Figure 5.
MALDI TOF spectra of (A) rTM456 (B) and rTM456-glycopolymer 
(Matrix:Water:Acetonitrile:Trifluoroacetic Acid, 50:50:0.1, v/v ratio).
Scheme 1.
Synthesis of O-cyanate chain-end functionalized glycopolymer with lactose pendant units 
via CMFRP.
Table 1
Protein C activation activities of rTM456 and rTM456-glycopolymer conjugate
rTM456 rTM456-glycopolymer
Km(pM) 0.75±0.2 0.81±0.12
kcat (Min-1) 0.25±0.08 0.19±0.20
0.29±0.11 0.20±0.15
Standard deviations among the three measurements are shown after the ‘±’ sign.
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